Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Reports Fourth Quarter and 2008 Financial Results
March 10th, 2009
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY): – Established Human Proof of Concept with an RNAi Therapeutic, a First for the Industry – – Advanced Pipeline with ALN-RSV and ALN-VSP Clinical Programs – – Continued Scientific Leadership, Consolidation of Leading Intellectual Property, and Formed Four Major Alliances in Last 12 Months with $175 Million in Realized Funding – – Ended 2008 with $513 Million in Cash and Earned $96 Million in Revenues, a Near Doubling of 2007 Revenues – – Net Loss Narrowed in 2008 as Compared to 2007 Due to Strong Revenues – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, reported its consolidated financial results for the fourth...
Source: Cancer Weekly (2009-03-10)
|
